Therefore, targeting ADAM17 presents a dual therapeutic opportunity in the context of COVID-19 which can help to modulate the inflammatory response and alleviate the cytokine storm associated with severe disease, but also to impede SARS-CoV-2 entry and propagation. This evidence concerns the gene ADAM17 and COVID-19.